|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Sternberg CN: The treatment of advanced
bladder cancer. Ann Oncol. 6:113–126. 1995.
|
|
3.
|
Fagg SL, Dawson-Edwards P, Hughes MA,
Latief TN, Rolfe EB and Fielding JW: Cis-diamminedichloroplatinum
(DDP) as initial treatment of invasive bladder cancer. Br J Urol.
56:296–300. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Raghavan D, Pearson B, Coorey G, et al:
Intravenous cis-platinum for invasive bladder cancer. Safety and
feasibility of a new approach. Med J Aust. 140:276–278.
1984.PubMed/NCBI
|
|
5.
|
Advanced Bladder Cancer Meta-analysis
Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer:
a systematic review and meta-analysis. Lancet. 361:1927–1934. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Grossman HB, Natale RB, Tangen CM, et al:
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy
alone for locally advanced bladder cancer. N Engl J Med.
349:859–866. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Von der Maase H, Sengelov L, Roberts JT,
et al: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005.
|
|
8.
|
Cam K, Yildirim A, Ozveri H, Turkeri L and
Akdas A: The efficacy of neoadjuvant chemotherapy in invasive
bladder cancer. Int Urol Nephrol. 33:49–52. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Dogliotti L, Carteni G, Siena S, et al:
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as
first-line chemotherapy in advanced transitional cell carcinoma of
the urothelium: results of a randomized phase 2 trial. Eur Urol.
52:134–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bamias A, Moulopoulos LA, Koutras A, et
al: The combination of gemcitabine and carboplatin as first-line
treatment in patients with advanced urothelial carcinoma. A Phase
II study of the Hellenic Cooperative Oncology Group. Cancer.
106:297–303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nikolova DN, Zembutsu H, Sechanov T, et
al: Genome-wide gene expression profiles of thyroid carcinoma:
identification of molecular targets for treatment of thyroid
carcinoma. Oncol Rep. 20:105–121. 2008.PubMed/NCBI
|
|
12.
|
Golub TR, Slonim DK, Tamayo P, et al:
Molecular classification of cancer: class discovery and class
prediction by gene expression monitoring. Science. 286:531–537.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Takata R, Katagiri T, Kanehira M, et al:
Predicting response to methotrexate, vinblastine, doxorubicin, and
cisplatin neoadjuvant chemotherapy for bladder cancers through
genome-wide gene expression profiling. Clin Cancer Res.
11:2625–2636. 2005. View Article : Google Scholar
|
|
14.
|
Yamanaka Y, Tamari M, Nakahata T and
Nakamura Y: Gene expression profiles of human small airway
epithelial cells treated with low doses of 14- and 16-membered
macrolides. Biochem Biophys Res Commun. 287:198–203. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Takata R, Katagiri T, Kanehira M, et al:
Validation study of the prediction system for clinical response of
M-VAC neoadjuvant chemotherapy. Cancer Sci. 98:113–117. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zehorai E, Yao Z, Plotnikov A and Seger R:
The subcellular localization of MEK and ERK – a novel nuclear
translocation signal (NTS) paves a way to the nucleus. Mol Cell
Endocrinol. 314:213–220. 2009.
|
|
17.
|
Matsumoto K, Nagahara T, Okano J and
Murawaki Y: The growth inhibition of hepatocellular and
cholangiocellular carcinoma cells by gemcitabine and the roles of
extracellular signal-regulated and checkpoint kinases. Oncol Rep.
20:863–872. 2008.PubMed/NCBI
|
|
18.
|
Yokoi K and Fidler IJ: Hypoxia increases
resistance of human pancreatic cancer cells to apoptosis induced by
gemcitabine. Clin Cancer Res. 10:2299–2306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Iwao-Koizumi K, Matoba R, Ueno N, et al:
Prediction of docetaxel response in human breast cancer by gene
expression profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Esrig D, Elmajian D, Groshen S, et al:
Accumulation of nuclear p53 and tumor progression in bladder
cancer. N Engl J Med. 331:1259–1264. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Cote RJ, Dunn MD, Chatterjee SJ, et al:
Elevated and absent pRb expression is associated with bladder
cancer progression and has cooperative effects with p53. Cancer
Res. 58:1090–1094. 1998.PubMed/NCBI
|
|
22.
|
Oosterhuis JW, Schapers RF,
Janssen-Heijnen ML, Smeets AW and Pauwels RP: MIB-1 as a
proliferative marker in transitional cell carcinoma of the bladder:
clinical significance and comparison with other prognostic factors.
Cancer. 88:2598–2605. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Stein JP, Ginsberg DA, Grossfeld GD, et
al: Effect of p21WAF1/CIP1 expression on tumor progression in
bladder cancer. J Natl Cancer Inst. 90:1072–1079. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Inoue K, Slaton JW, Karashima T, et al:
The prognostic value of angiogenesis factor expression for
predicting recurrence and metastasis of bladder cancer after
neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res.
6:4866–4873. 2000.
|
|
25.
|
Rho SB, Woo JS, Chun T and Park SY:
Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in
ovarian carcinoma cells. Biotechnol Lett. 31:23–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Gery S, Xie D, Yin D, et al: Ovarian
carcinomas: CCN genes are aberrantly expressed and CCN1 promotes
proliferation of these cells. Clin Cancer Res. 11:7243–7254. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Dao D, Frank D, Qian N, et al: IMPT1, an
imprinted gene similar to polyspecific transporter and multi-drug
resistance genes. Hum Mol Genet. 7:597–608. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Okabe M, Szakacs G, Reimers MA, et al:
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell line to
identify drug uptake transporters. Mol Cancer Ther. 7:3081–3091.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lossos IS, Czerwinski DK, Alizadeh AA, et
al: Prediction of survival in diffuse large-B-cell lymphoma based
on the expression of six genes. N Engl J Med. 350:1828–1837. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ma XJ, Wang Z, Ryan PD, et al: A two-gene
expression ratio predicts clinical outcome in breast cancer
patients treated with tamoxifen. Cancer Cell. 5:607–616. 2004.
View Article : Google Scholar
|
